DK1061920T3 - Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering - Google Patents

Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering

Info

Publication number
DK1061920T3
DK1061920T3 DK99907346T DK99907346T DK1061920T3 DK 1061920 T3 DK1061920 T3 DK 1061920T3 DK 99907346 T DK99907346 T DK 99907346T DK 99907346 T DK99907346 T DK 99907346T DK 1061920 T3 DK1061920 T3 DK 1061920T3
Authority
DK
Denmark
Prior art keywords
formulation
sulfinyl
benzimidazole
pyridinyl
methyl
Prior art date
Application number
DK99907346T
Other languages
English (en)
Inventor
Kristian Lund Henriksen
Helle Kann
Karen Eichstedt Soerensen
Soeren Bols Pedersen
Original Assignee
Gea Farmaceutisk Fabrik As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1061920(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As
Application granted granted Critical
Publication of DK1061920T3 publication Critical patent/DK1061920T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99907346T 1998-03-20 1999-03-17 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering DK1061920T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
PCT/DK1999/000137 WO1999048498A1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation

Publications (1)

Publication Number Publication Date
DK1061920T3 true DK1061920T3 (da) 2002-07-15

Family

ID=8093069

Family Applications (2)

Application Number Title Priority Date Filing Date
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK99907346T DK1061920T3 (da) 1998-03-20 1999-03-17 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs

Country Status (20)

Country Link
US (1) US6391342B1 (da)
EP (1) EP1061920B1 (da)
AR (1) AR014753A1 (da)
AT (1) ATE218863T1 (da)
AU (1) AU744596B2 (da)
CA (1) CA2323536C (da)
CZ (1) CZ291943B6 (da)
DE (1) DE69901804T2 (da)
DK (2) DK173431B1 (da)
EA (1) EA002502B1 (da)
ES (1) ES2177246T3 (da)
HU (1) HU226580B1 (da)
IS (1) IS2265B (da)
NO (1) NO20004667L (da)
NZ (1) NZ507115A (da)
PL (1) PL192437B1 (da)
TR (1) TR200002696T2 (da)
TW (1) TW529951B (da)
WO (1) WO1999048498A1 (da)
ZA (1) ZA200004757B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526022T1 (de) 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2376202C (en) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CN1874764B (zh) * 2003-10-10 2012-08-01 埃法尔姆公司 含有银杏提取物的持续释放微粒及其制备方法
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
EP1746980B1 (en) 2004-05-07 2011-11-02 Nycomed GmbH Pharmaceutical dosage form comprising pellets as well as its manufacturing process
JP5563735B2 (ja) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
WO2007075381A2 (en) * 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (da) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
ATE262332T1 (de) 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
WO1998040377A1 (en) 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Also Published As

Publication number Publication date
ES2177246T3 (es) 2002-12-01
ZA200004757B (en) 2001-05-30
PL192437B1 (pl) 2006-10-31
DE69901804D1 (de) 2002-07-18
NO20004667D0 (no) 2000-09-19
EP1061920A1 (en) 2000-12-27
DK39798A (da) 1999-09-21
TR200002696T2 (tr) 2000-12-21
NO20004667L (no) 2000-11-09
IS2265B (is) 2007-07-15
EA002502B1 (ru) 2002-06-27
DE69901804T2 (de) 2002-12-12
AR014753A1 (es) 2001-03-28
CA2323536C (en) 2009-05-19
DK173431B1 (da) 2000-10-23
EP1061920B1 (en) 2002-06-12
CZ291943B6 (cs) 2003-06-18
HU226580B1 (en) 2009-04-28
US6391342B1 (en) 2002-05-21
PL342840A1 (en) 2001-07-16
CZ20003458A3 (cs) 2001-03-14
HUP0101178A2 (hu) 2001-08-28
ATE218863T1 (de) 2002-06-15
AU2714899A (en) 1999-10-18
AU744596B2 (en) 2002-02-28
WO1999048498A1 (en) 1999-09-30
CA2323536A1 (en) 1999-09-30
TW529951B (en) 2003-05-01
NZ507115A (en) 2002-09-27
IS5628A (is) 2000-09-13
EA200000970A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
DK1061920T3 (da) Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering
DK0984773T3 (da) Farmaceutisk formulering med omeprazol
BR9508292A (pt) Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
EE04631B1 (et) Meetod farmatseutilise ravimvormi aerosoolistamiseks ja pihustusseade
DE60031119D1 (de) Richtbohrvorrichtung und -verfahren
DK0818454T3 (da) Benzimidazolderivater med antihistamin-aktivitet
DK1150912T3 (da) Enhed til baneoprulning, -afskæring og -overföring
TR200000534A3 (tr) Bir ilacin uygulanmasi için metot ve sistem
NO20001711L (no) FremgangsmÕte for kommunikasjon med et transportsystem
DE60016291D1 (de) Verbindungssystem und -verfahren
EE200100383A (et) L-fenüülefriinvesinikkloriidi valmistamise meetod
NO20015510D0 (no) Medikament for lokal påföring
EE04154B1 (et) Omeprasooli valmistamise meetod
GB2352058B (en) System and method for automatically managing semiconductor production bays
NO994340D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
AU2000258410A8 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
NO994209D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler og nye forbindelser til anvendelse for dette formÕl
FI19992465A (fi) Menetelmä ja järjestelmä esisynkroinnin luotettavuuden parantamiseksi solukkojärjestelmässä
IT1315240B1 (it) Appendiabiti perfezionato per vestiti e metodo di fabbricazionerelativo.
NL1011479A1 (nl) Doseerinrichting en werkwijze voor het vormen daarvan.
BR0015220A (pt) Procedimento melhorado para a preparação de derivados de benzimidazol adequados como fármacos antiulcerosos, principalmente omeprazol ou pantoprazol
FI990911A0 (fi) Menetelmä ja järjestelmä puhelun siirtämiseksi
EE200100448A (et) Bifenüül-2-karboksüülhappe derivaatide valmistamise meetod
NL1008408A1 (nl) Inrichting en werkwijze voor het verven.